Northwestern University
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Northwestern University sits in the top decile of US sponsors by registered trial count (#23 of 15,742 sponsors by registered trial count).
Northwestern University: 1,209 sponsored US clinical trials, 187 recruiting.
Northwestern University sponsors 1,209 registered US clinical trials on ClinicalTrials.gov, 187 of them currently recruiting, and 767 completed. 114 of these trials are in Phase 3-4 (later-stage) and 295 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Depression, with 11 trials.
Top-decile sponsor footprint
Northwestern University ranks in the top decile of sponsors by registered trial count (#23 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
767 of 912 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (84.1%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
1,209 total, page 24 of 25
Hematopoietic Stem Cell Therapy for Patients With Refractory Myasthenia Gravis
NCT00424489
Neuraxial Versus Systemic Analgesia for Latent Phase Labor Effect on Rate of Operative Delivery
NCT00380978
Total Parenteral Nutrition-Associated Liver Disease
NCT00031135
PS-341 in Treating Women With Metastatic Breast Cancer
NCT00028639
Oltipraz in the Prevention of Lung Cancer in People Who Smoke
NCT00006457
Alemtuzumab in Treating Patients With Relapsed or Refractory Advanced Mycosis Fungoides or Sézary Syndrome
NCT00057967
Rebeccamycin Analogue in Treating Patients With Refractory Stage III or Stage IV Ovarian Epithelial Cancer
NCT00006262
Arsenic Trioxide in Treating Patients With Relapsed or Refractory Hodgkin's Disease
NCT00005595
Radiolabeled Monoclonal Antibody Therapy and High-Dose Chemotherapy Followed By Autologous Peripheral Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
NCT00058292
Analysis of Blood and Bone Marrow to Detect Residual Disease in Patients With Previously Treated Hairy Cell Leukemia
NCT00005619
Peripheral Blood Lymphocyte Therapy to Prevent Lymphoproliferative Disorders Caused by Epstein-Barr Virus in Patients Who Have Undergone Transplantation
NCT00005606
Tamoxifen to Prevent Bone Loss and Heart Disease in Premenopausal Women Receiving Chemotherapy for Stage I or Stage II Breast Cancer
NCT00005605
Arsenic Trioxide in Treating Patients With Acute Myeloid Leukemia
NCT00005795
Fluorouracil-Uracil and Leucovorin in Treating Women With Metastatic Breast Cancer
NCT00005608
Combination Chemotherapy in Treating Patients With Advanced Solid Tumors
NCT00004913
Endoscopic Placement of Metal Stent in Patients With Cancer-Related Bowel Obstruction
NCT00004911
Endoscopic Placement of Metal Stents in Treating Patients With Cancer- Related Duodenal Obstruction
NCT00004910
Megestrol and Exercise in Treating Patients With Cancer-Related Weight Loss
NCT00004912
Exercise Plus Epoetin Alfa in Treating Cancer Patients Who Have Anemia-Related Fatigue
NCT00004914
Peripheral Stem Cell Transplantation in Treating Patients With Breast Cancer or Hematologic Cancer
NCT00006225
Effect of Chemotherapy Given Either by Mouth or by Infusion on the Quality of Life of Patients With Recurrent Ovarian Epithelial Cancer
NCT00004909
Radiation Therapy and Cyclophosphamide Plus Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Hodgkin's Disease or Non-Hodgkin's Lymphoma
NCT00004908
Busulfan and Cyclophosphamide Followed by Bone Marrow Transplantation in Treating Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome
NCT00004896
Melphalan Followed by Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma
NCT00004165
Bone Marrow and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer
NCT00004232
Bone Marrow Transplantation in Treating Patients With Multiple Myeloma, Chronic Phase Chronic Myelogenous Leukemia, or Agnogenic Myeloid Metaplasia
NCT00004181
Amifostine in Treating Patients With Ovarian Epithelial Cancer Who Are Receiving Chemotherapy
NCT00004166
Stem Cell Transplantation in Treating Patients With Hematologic Cancer
NCT00004904
Octreotide as Palliative Therapy for Cancer-Related Bowel Obstruction That Cannot Be Removed by Surgery
NCT00004895
Chemotherapy, Filgrastim, and Stem Cell Transplantation With Radiation Therapy in Treating Patients With Stage III or Stage IV Breast Cancer
NCT00004172
Combination Chemotherapy, Bone Marrow or Peripheral Stem Cell Transplantation, and/or Biological Therapy in Treating Patients With Stage III or Stage IV Mantle Cell Lymphoma
NCT00004231
Chemotherapy Plus Bone Marrow Transplantation and Filgrastim in Treating Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome
NCT00004899
Peripheral Stem Cell Transplantation Following Radiation Therapy in Treating Patients With Hodgkin's Disease or Non-Hodgkin's Lymphoma
NCT00004171
Irinotecan in Treating Patients With Metastatic or Recurrent Breast Cancer
NCT00004182
Combination Chemotherapy Followed By Peripheral Stem Cell Transplantation in Treating Patients With Advanced Breast Cancer
NCT00004174
Chemotherapy and Radiation Therapy Plus Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Relapsed or Refractory T-cell Lymphoma, Hodgkin's Lymphoma, or Non-Hodgkin's Lymphoma
NCT00004907
Radiation Therapy and Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With High-Grade Lymphoma or Acute Lymphoblastic Leukemia
NCT00004898
Captopril in Treating Patients Undergoing Bone Marrow or Stem Cell Transplantation
NCT00004230
Combination Chemotherapy and Interferon Alfa Followed by Surgery and/or Radiation Therapy in Treating Patients With Stage I, Stage II, or Stage III Esophageal Cancer
NCT00004897
Peripheral Stem Cell Transplantation to Prevent Neutropenia in Patients Receiving Chemotherapy for Relapsed or Refractory Non-Hodgkin's Lymphoma
NCT00005787
Detection of Biomarkers in Abnormal Cervical Cells in Women With Abnormal Pap Test Results
NCT00004091
Irinotecan Plus Gemcitabine in Treating Patients With Unresectable or Metastatic Solid Tumors
NCT00004095
Carboplatin Plus Vinorelbine in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer
NCT00004096
Gemcitabine and Cisplatin in Treating Patients With Metastatic or Recurrent Solid Tumors
NCT00004090
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer
NCT00004093
Ifosfamide, Teniposide, and Paclitaxel in Treating Patients With Relapsed Non-Hodgkin's Lymphoma
NCT00004916
Improving Outcome in Schizophrenia Through Identification of Genetic Risk Factors
NCT00178932
Docetaxel, Doxorubicin, and Cyclophosphamide in Treating Women With Stage III Breast Cancer
NCT00004175
Raloxifene in Treating Patients With Persistent or Recurrent Endometrial Cancer
NCT00004915
Midlife Cholesterol Study
NCT00361075
What is open in the Northwestern University pipeline
187 recruiting of 1,209 indexed (15% open); 767 completed (63%).
Phase mix: 114 late (III/IV) vs 295 early (I/II) (early-phase heavy).
Top condition: Depression (11 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Northwestern University: open-pipeline peers nationwide
Peers matched on 1,209 registered trials and 15% open enrollment, not the therapeutic-area sidebar.
Northwestern University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 1,209 trials (± recruiting share)
- Emory University · 1,208 trials · 17% recruiting
- University of Pittsburgh · 1,238 trials · 13% recruiting
- NYU Langone Health · 1,164 trials · 17% recruiting
- University of Alabama at Birmingham · 1,160 trials · 19% recruiting
Sponsors near 15% open enrollment (± trial volume)
- Brigham and Women's Hospital · 15% recruiting · 937 trials
- Incyte Corporation · 15% recruiting · 239 trials
- Nationwide Children's Hospital · 15% recruiting · 188 trials
- University of Michigan Rogel Cancer Center · 15% recruiting · 292 trials
Related
What to do with this Northwestern University page
1,209 registered trials is a research-attention snapshot, not an endorsement of Northwestern University or any single study.
- 187 of Northwestern University's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Depression is the condition Northwestern University studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Depression trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Northwestern University pipeline card: 1,209 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.